NASDAQ:SMMT | Free Cash Flow | Summit Therapeutics Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2019-01-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$122.29M$245,000.00-$122.54M
2025-12-31-$101.94M$164,000.00-$102.1M
2025-03-31-$61.17M$422,000.00-$61.59M
2024-12-31-$48.67M$14,000.00-$48.69M
2024-03-31-$30.13M$4,000.00-$30.14M
2023-12-31-$19.46M$2,000.00-$19.46M
2023-03-31-$13.13M$53,000.00-$13.18M
2022-12-31$5.19M-$10,000.00$5.18M
2022-03-31-$19M$361,000.00-$19.36M
2021-12-31-$9.18M$120,000.00-$9.3M
2021-03-31-$20.67M$39,000.00-$20.71M
2020-12-31-$7.97M$50,000.00-$8.02M
2020-03-31-$4.96M$30,000.00-$4.99M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$322.93M$657,000.00-$323.59M
2024-12-31-$142.11M$139,000.00-$142.25M
2023-12-31-$76.76M$128,000.00-$76.89M
2022-12-31-$41.58M$624,000.00-$42.21M
2021-12-31-$72.59M$306,000.00-$72.89M
2020-12-31-$48.11M$421,000.00-$48.53M
2019-12-31-$20.76M$205,000.00-$20.96M
2019-01-31-$35.11M$157,000.00-$35.26M-324.44%

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.